HealthTech Founders Lose Millions in Hidden Deal Clauses

Bessemer's 2026 Forecast: A Market Divided on Risk

The landscape for healthcare funding has shifted dramatically since the start of the year.

According to the 'State of Health AI 2026' report published by Bessemer Venture Partners on 22 January, the sector is experiencing a bifurcation.

Top-tier companies continue to attract capital at aggressive valuations, while the mid-market struggles to secure funding on favourable terms.

This divergence gives investors significant leverage to dictate terms.

Bessemer's data indicates that while the total volume of investment in Health AI remains high, the conditions attached to this capital have become far more stringent.

Investors are no longer willing to bet on future potential alone; they are demanding structural protections that guarantee minimum returns.

This shift fundamentally alters the risk profile for founders.

Where once they shared the upside and downside equally with investors, they now increasingly bear the brunt of the downside while seeing their upside capped by preferential deal terms.

• The 'State of Health AI 2026' identifies a consolidation trend where larger players absorb innovative startups.
• Bessemer Venture Partners notes that regulatory clarity in the EU is driving a new wave of AI-focused diagnostics funding.
• Investors are prioritising companies with clear, near-term revenue paths over long-term scientific bets.

The report highlights that the 'winner-takes-all' dynamic in Health AI is accelerating.

Investors are piling capital into market leaders they believe will dominate specific verticals, such as radiology AI or drug discovery.

This concentration of capital allows these lead investors to impose rigorous deal structures.

Founders, desperate to secure the resources needed to compete in this high-stakes environment, often feel compelled to accept these terms without adequate pushback.

The result is a generation of HealthTech companies that are technically well-funded but financially fragile from an equity perspective.

The Bessemer analysis suggests that this trend will continue throughout 2026, making it imperative for founders to understand the long-term implications of today's deal structures.

Inside the Term Sheet: Liquidation Preferences and Clawbacks

The primary mechanism eroding founder value is the liquidation preference.

This clause determines who gets paid first and how much they get when a company is sold or goes public.

In a standard 1x non-participating preference, investors get their money back before founders see a cent, but then share in the remaining proceeds.

However, the analysis from healthcare.digital points to a rise in participating preferred structures and multiples higher than 1x.

In a participating preferred deal, investors get their initial investment back *and* then share in the proceeds as if they hadn't been paid back.

This double-dipping can drastically reduce the founder's slice of the exit pie.

For example, in a €50 million exit where an investor holds €20 million in participating preferred stock with a 2x liquidation preference, the investor takes €40 million off the top immediately.

The remaining €10 million is then split according to ownership percentages.

If the founder owns 40%, they receive just €4 million, despite owning a large chunk of the company.

This mathematical reality is often lost in the celebration of a funding round.

• Clawback clauses are increasingly used to reclaim unvested shares if a founder leaves or is terminated.
• Anti-dilution provisions, specifically 'full ratchet' clauses, can severely punish founders if the company raises money at a lower valuation later.
• Earn-outs, which tie additional payments to future performance milestones, are becoming standard in European MedTech acquisitions.

These structures are not inherently malicious; they reflect investor caution in a volatile market.

HealthTech and MedTech startups face long development cycles, regulatory hurdles, and significant clinical risk.

Investors use these terms to mitigate the possibility of losing their entire investment.

However, the imbalance has tipped too far, argues the healthcare.digital report.

When deal structures protect investors to such an extent that founders are disincentivised, the ecosystem suffers.

Innovation requires motivated entrepreneurs.

If the financial reward for building a successful company is stripped away by complex legal clauses, the best talent may migrate to other sectors or choose not to start companies at all.

The report urges founders to seek legal counsel who specialise in venture capital term sheets and to negotiate these clauses aggressively.

The Built In 56: Success Stories With Hidden Costs

To understand the real-world impact of these deal structures, one must look at the companies currently dominating the market.

Built In's recent list of '56 Top Healthcare Startups and Healthtech Companies', published on 1 April 2024, provides a snapshot of the sector's elite.

These companies, ranging from digital therapeutics to AI-driven diagnostics, are often cited as success stories.

Yet, behind the scenes, many of these firms have navigated complex funding paths that likely involved the very structures now under scrutiny.

The list includes companies that have raised hundreds of millions of euros.

While these capital injections fuel growth and product development, they also set the stage for high-stakes exit negotiations.

If a company on this list is acquired for a sum that does not significantly exceed its total preferred capital, the founders may realise minimal gains.

This creates a scenario where a 'successful' acquisition yields little personal wealth for the founding team.

• The Built In list highlights the diversity of the sector, including Health IT, MedTech, and Digital Health.
• Many of the 56 listed companies have participated in multiple funding rounds, increasing the complexity of their cap tables.
• The competitive pressure to be featured on such lists can drive founders to accept unfavourable terms to maintain momentum.

The prestige associated with being a top startup can be a double-edged sword.

Founders feel pressure to keep raising money at higher valuations to maintain their status.

This cycle can lead to 'down rounds' or flat rounds if market conditions tighten, triggering anti-dilution protections that further erode founder equity.

The healthcare.digital analysis suggests that many of the companies celebrated in industry lists may actually be 'trap deals' for the founders.

They have built valuable businesses, but the financial engineering of their funding rounds has effectively transferred the economic value of that success to the investors.

This dynamic is particularly acute in Europe, where exit values are generally lower than in the United States, making liquidation preferences bite harder.

A €100 million exit in Berlin might be celebrated, but if the investor has a 2x liquidation preference on €60 million of investment, the founder's payout is negligible.

Why HealthTech Deals Carry More Risk Than Fintech

The prevalence of aggressive deal structures in HealthTech is not random; it is a direct response to the unique risks of the sector.

Unlike software or fintech, where a product can be iterated and deployed rapidly, HealthTech involves clinical validation, regulatory approval, and integration with legacy hospital systems.

These factors extend the time to market and increase the burn rate.

Investors argue that the higher risk justifies higher protections.

A clinical trial failure can wipe out a company's value overnight.

In such an event, investors want to ensure they recover at least some of their capital.

This reality has led to the standardisation of terms that are rare in other technology sectors.

However, experts point out that this risk aversion is often over-applied.

Not all HealthTech companies carry the same binary risk profile.

A Health IT company streamlining hospital administration faces very different risks than a MedTech firm developing a novel surgical robot.

Treating them the same in term sheets is inefficient and unfair to founders.

• Regulatory hurdles in the EU, such as the MDR (Medical Device Regulation), have increased development costs and timelines.
• The integration of AI into healthcare adds a layer of regulatory complexity that investors find difficult to underwrite.
• Reimbursement uncertainty remains a major hurdle for digital health startups across Europe.

The 'State of Health AI 2026' report by Bessemer Venture Partners touches on this, noting that investors are becoming more discerning about which sub-sectors of Health AI they back.

This discernment is reflected in the deal terms.

High-risk areas like drug discovery AI might command harsher terms, while administrative AI might secure more founder-friendly structures.

The problem is that the market has not yet fully adjusted to this nuance.

Many investors apply a blanket 'HealthTech premium' to their term sheets, regardless of the specific company's risk profile.

Founders must therefore be prepared to argue their specific case.

They need to demonstrate why their particular risk profile warrants a more equitable deal structure.

This requires a deep understanding of both their own business model and the mechanics of venture capital financing.

Negotiating the Exit: What Founders Must Demand Now

The current market dynamics demand a new approach from HealthTech founders.

Accepting the 'standard' term sheet is no longer viable.

The healthcare.digital report urges entrepreneurs to focus on three key areas: liquidation preferences, vesting schedules, and exit rights.

Founders should push for a 1x non-participating liquidation preference.

This ensures investors are made whole in a modest exit but allows founders to participate fully in the upside once that threshold is met.

They should also scrutinise anti-dilution clauses, rejecting 'full ratchet' provisions in favour of weighted-average calculations.

Furthermore, founders must pay close attention to vesting.

Single-trigger acceleration, which accelerates vesting upon a change of control, is becoming rare.

Founders should negotiate for double-trigger acceleration, which vests shares if they are fired without cause shortly after an acquisition.

• Transparency with co-founders regarding cap table dynamics is essential to avoid conflicts later.
• Founders should seek investors who have a track record of founder-friendly exits in the healthcare space.
• Understanding the implications of the EU AI Act on company valuation can provide leverage during negotiations.

The narrative of the 'brilliant founder' is often used to mask the reality of the 'controlled employee'.

Investors hold the purse strings and, increasingly, the contractual rights to control the company's destiny.

However, talent remains the scarcest resource in HealthTech.

The best founders, those who can navigate clinical trials and regulatory mazes, have the power to push back.

The Bessemer report and the Built In list highlight the immense value being created in this sector.

The challenge for founders is ensuring they capture a fair share of that value.

As the market evolves through 2026, those who understand the mechanics of deal structures will be the ones who truly succeed.

The rest risk becoming mere employees in their own companies, watching the rewards of their labour flow to those who provided the capital.

The time for founders to educate themselves is now, before the next funding round is signed.